Australian company Imugene (ASX:IMU) has released new clinical data showing an 82 per cent overall response rate in its Phase 1b trial of azer-cel, the company’s allogeneic, off-the-shelf CD19 CAR T therapy for patients with relapsed or refractory diffuse large B-cell lymphoma. …
Australian company reports high response rate in trial of off-the-shelf CAR-T therapy
December 1, 2025 Australian Biotech
Latest Video
New Stories
-
Patients and clinicians defend MS treatment choice during review stakeholder meeting
November 5, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News -
Sydney summit program focused on the reshaping power of AI
November 4, 2026 - - Latest News -
Is the reluctance to revisit term limits because they are such an obvious change?
November 4, 2026 - - Latest News -
Does new report suggest that patient voice reforms are stalling?
November 4, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News